83 computer-science "https:" "https:" "https:" "NIST" Postdoctoral positions at Northeastern University
Sort by
Refine Your Search
-
Category
-
Country
-
Field
-
constitutive modeling of anisotropic and compressible materials. Minimum Qualifications Required PhD in mechanical engineering, aerospace engineering, materials science and engineering, civil engineering
-
submissions received before February 18th, 2025. We especially encourage those from underrepresented groups in science to apply. Position Type Research Additional Information Northeastern University
-
locus coeruleus in cognition. Researchers must possess a doctoral degree in Psychology, Cognitive Science, Neuroscience, or a related field. We seek post-doctoral researchers who aim to take leading
-
. About Alnylam We are the leader in RNAi therapeutics – a revolutionary approach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science
-
Lab places a strong emphasis on open scientific exchange, mentorship, and a team-oriented culture in which postdoctoral researchers play a central role in shaping both the science and the intellectual
-
. About GSK GSK is a focused biopharma company with strong momentum and big ambitions, to unite science, technology, and talent to get ahead of disease together. We aim to positively impact the health of
-
more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with
-
on Nobel Prize-winning science, Alnylam has delivered the breakthroughs that made RNAi therapeutics possible and are just at the beginning of what’s possible. Our deep pipeline, late-stage programs